Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Clinical Study of Combined Radical Operation With Postoperative Adjuvant Chemotherapy and Prophylactic Cranial Irradiation in pT1-2N0M0 Stage of Small Cell Lung Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03514849
Recruitment Status : Recruiting
First Posted : May 2, 2018
Last Update Posted : August 7, 2018
Sponsor:
Information provided by (Responsible Party):
Peng Zhang, Shanghai Pulmonary Hospital, Shanghai, China

Brief Summary:

At present, for participants with cT1-2N0 small cell lung cancer (SCLC), the International guidelines recommend surgical radical resection (lobectomy + systematic lymph node sampling or cleaning); If the postoperatively pathological examination is confirmed to be in pT1-2N0 stage, a single postoperative adjuvant chemotherapy (combining etoposide with cisplatin) is recommended. If participants are difficult to tolerate the side effects of cisplatin, the investigators can replace cisplatin by carboplatin in the adjuvant chemotherapy scheme. Participants with pT1-2N0 SCLC are not recommended to receive postoperative chest-assisted radiotherapy. For participants with pT1-N0 SCLC after specific surgical resection, prophylactic cranial irradiation (PCI) is currently recommended. But this recommendation is currently lacking the support of research evidence.

The main purpose of this study is to study the prognostic effects of PCI on participants with pT1-2N0 stage small cell lung cancer (SCLC) who have received radical surgery and postoperative adjuvant chemotherapy.

The main endpoint of this study is to observe the total survival rate (5-year OS%) in 5 years.

The secondary outcome measures include 5 years of disease-free survival (5-year DFS%), disease-free survival (DFS), overall survival (OS), surgical complications, resection rates, quality of life (QoL), and exploration of biomarkers (tumor tissue).

This is a two-arm, open, multicentral clinical study designed to compare the 5-year OS% of participants receiving or not receiving PCI for pT1-2N0 stage small cell lung cancer (SCLC) with radical surgery plus postoperative adjuvant chemotherapy. Previous literature reports that the 5-year OS% of participants with pT1-2N0 period SCLC who have received surgical resection is about 50%. Assuming that PCI can increase 5 years OS% by 10%, then enrolling 320 participants in the group can guarantee 70% degree of certainty with observing a unilateral significant difference α< 0.1. Taking about 10% of the follow-up loss rate into account, the investigators expect to enroll 360 participants.

Dividing the 360 participants divided into two groups randomly, each group is composed of 180 people. All participants received lobectomy plus mediastinal lymph node dissection or systematic lymph node sampling. Participants in the control group are enrolled in the follow-up, and the participants in research group will receive PCI by 25gy/10fx.


Condition or disease Intervention/treatment Phase
Small-cell Lung Cancer Procedure: prophylactic cranial irradiation (PCI) Procedure: lobectomy + mediastinal lymph node dissection or systematic lymph node sampling Drug: postoperative adjuvant chemotherapy Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 360 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Clinical Study of Combined Radical Operation With Postoperative Adjuvant Chemotherapy and Prophylactic Cranial Irradiation in pT1-2N0M0 Stage of Small Cell Lung Cancer
Estimated Study Start Date : August 2018
Estimated Primary Completion Date : March 2021
Estimated Study Completion Date : March 2026

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lung Cancer

Arm Intervention/treatment
Experimental: PCI group Procedure: prophylactic cranial irradiation (PCI)
Patients in the control group are enrolled in the follow-up, and the patients in research group will receive prophylactic cranial irradiation (PCI) by 25 gy/10 fx.

Procedure: lobectomy + mediastinal lymph node dissection or systematic lymph node sampling
lobectomy + mediastinal lymph node dissection or systematic lymph node sampling

Drug: postoperative adjuvant chemotherapy
If the postoperatively pathological examination of the patient is confirmed to be in pT1-2N0 stage, a single postoperative adjuvant chemotherapy (combining etoposide with cisplatin) is recommended. If patients are difficult to tolerate the side effects of cisplatin, we can replace cisplatin by carboplatin in the adjuvant chemotherapy scheme.

Placebo Comparator: Control group Procedure: lobectomy + mediastinal lymph node dissection or systematic lymph node sampling
lobectomy + mediastinal lymph node dissection or systematic lymph node sampling

Drug: postoperative adjuvant chemotherapy
If the postoperatively pathological examination of the patient is confirmed to be in pT1-2N0 stage, a single postoperative adjuvant chemotherapy (combining etoposide with cisplatin) is recommended. If patients are difficult to tolerate the side effects of cisplatin, we can replace cisplatin by carboplatin in the adjuvant chemotherapy scheme.




Primary Outcome Measures :
  1. 5-year overall survival rate(5-y OS%) [ Time Frame: From the completion of the intervention to 5 years. ]
    Five-year survival rate measures survival at 5 years after surgery.


Secondary Outcome Measures :
  1. 5-year disease-free survival rate (5-y DFS%) [ Time Frame: From the completion of the intervention to 5 years. ]
    The rate that the patients whose disease doesn't recur take up in the total patients from the start of randomization to 5 years.

  2. disease-free survival period [ Time Frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 40 months ]
    From the beginning of randomization to the time-point when the disease recurs or the patient dies due to disease progression.

  3. overall survival (OS) [ Time Frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months ]
    Patients die directly from the progression of SCLC or from an unrelated cause (for example, a car accident). When the precise cause of death is not specified, this is called the overall survival rate.

  4. surgery complications [ Time Frame: Within 2 weeks includes surgery and perioperative period. ]
    The complications related to the operations that happen in the perioperative period.

  5. removal rate [ Time Frame: Through study completion, an average of 1 year. ]
    The patients who are able to receive the radical resection.

  6. tumor biological makers [ Time Frame: Within 2 weeks includes surgery and perioperative period. ]
    To search the possible bio-makers for SCLC.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Signed informed consent;
  • Ability to follow research programs and follow-up procedures;
  • * Patient age ≥ 18 years old;
  • Histology or cytology confirmed as SCLC, chest enhancement ct, liver and adrenal ct, skull MRI, pet-ct/whole body bone scintigraphy, ebus puncture biopsy, etc. clearly as the t1-2n0 period of the initial treatment of patients (according to the UICC 2009 version of the phased standard);
  • Radical resection of the leaf, the postoperative confirmed margin negative, pathological stage of t1-2n0 stage of small cell lung cancer;
  • 4-week EP or EC regimen for adjuvant chemotherapy after surgery;
  • Physical status ECOG assessment is divided into 0~1;
  • Life expectancy at least 12 weeks;
  • The following laboratory tests conducted within 21 days of the end of the 4th cycle of chemotherapy confirmed that the patient's bone marrow, liver and kidney function met the requirements for participation in the study:
  • Hemoglobin ≥9.0 g/dl (can be maintained or exceeded by blood transfusion);-Neutrophil absolute Count (ANC) ≥1.5x109;
  • Platelet count ≥100x109/mm3;
  • Total bilirubin ≤ 1.5 times times normal value upper limit;
  • Alt and Straw transaminase ≤ 2.5 times times the normal value of the upper limit;
  • creatinine ≤ 1.5 times times the upper limit of normal value and creatinine clearance rate ≥60ml/min; -prothrombin Time International standardized ratio (INR) ≤1.5, and part of the clotting activity Time (APTT) ≤ 1.5 times times the normal value limit.
  • Patients who received a full or parenteral anticoagulation treatment had a minimum dose of anticoagulant for at least 2 weeks before entering clinical studies, and the results of the coagulation test were available for clinical trials within the limits of local treatment.
  • Women of childbearing age must be tested in pregnancy for 7 days prior to initiation of treatment and negative results.
  • Men and women of the appropriate age are required to use a reliable method of contraception until 30 days after withdrawal from the study before entering the trial. Reliable contraceptive methods will be judged by the principal researcher or designated person.

Exclusion Criteria:

  • Patients who have conducted any systemic anticancer therapy for SCLC, including cytotoxic drug therapy, targeted drug therapy and experimental therapy.
  • Localized radiotherapy for SCLC;
  • Patients with cancer other than SCLC in the five years prior to the start of the study.
  • Except for cervical in situ carcinoma, cured basal cell carcinoma, bladder epithelial tumor [including TA and tis];
  • Any unstable systemic disease (including active infections, uncontrolled high blood pressure, unstable angina pectoris, onset of angina in the last 3 months, congestive heart failure (≥ "NYHA" Grade II), cerebral infarction (6 months before the group), severe arrhythmia requiring medical treatment, Diagnosis with liver, kidney or metabolic disease;
  • Has or is currently suffering from interstitial lung disease;
  • Lack of full control of ocular inflammation or eye infections, or any condition that may cause such ocular diseases;
  • Known human immunodeficiency virus (HIV) infection;
  • Allergy to any kind of research drug;
  • Patients undergoing major surgery or severe trauma within 2 months prior to the first medication;
  • any negative absorption;
  • Pregnant or lactating women;
  • Other researchers do not think fit into the group.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03514849


Contacts
Layout table for location contacts
Contact: Peng Zhang, Doctor +86 021 651 15006 zhangpeng1121@outlook.com

Locations
Layout table for location information
China, Shanghai
Shanghai Pulmonary Hospital Recruiting
Shanghai, Shanghai, China, 200000
Contact: Peng Zhang, doctor         
Sponsors and Collaborators
Peng Zhang

Layout table for additonal information
Responsible Party: Peng Zhang, Director of science and education, Shanghai Pulmonary Hospital, Shanghai, China
ClinicalTrials.gov Identifier: NCT03514849     History of Changes
Other Study ID Numbers: k18-065
First Posted: May 2, 2018    Key Record Dates
Last Update Posted: August 7, 2018
Last Verified: August 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Neoplasms
Small Cell Lung Carcinoma
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms